COVID-19 vaccination and boosting appeared to play an essential function in defending most cancers sufferers in opposition to lengthy COVID throughout the Omicron wave, researchers reported yesterday in JAMA Community Open.
In a retrospective cohort research that concerned greater than 76,000 most cancers sufferers with excessive charges of vaccination and boosting in Singapore, a crew led by researchers from Singapore’s Communicable Illnesses Company and Singapore Common Hospital assessed the chance of long-COVID analysis and of signs suitable with lengthy COVID amongst these contaminated with SARS-CoV-2 from January 1 by means of December 31, 2022, when the Omicron variant was prevalent. They in contrast the chance in opposition to noninfected most cancers sufferers.
Whereas analysis suggests immunocompromised most cancers sufferers have the next danger of lengthy COVID than non-immunocompromised folks do, earlier research reporting long-COVID sequelae in most cancers sufferers have been performed primarily throughout pre-vaccination pandemic waves, the research authors famous.
“Emergence of milder Omicron variants and widespread vaccination might have altered lengthy COVID danger,” they wrote.
No important distinction between contaminated, non-infected sufferers
Among the many 76,807 sufferers within the research, 39,256 had SARS-CoV-2 an infection and 37,551 have been noninfected. The overwhelming majority (93.2%) of all sufferers within the research had acquired booster doses of COVID-19 vaccines. No important distinction in long-COVID analysis or suitable signs was noticed between contaminated and non-infected sufferers.
Though most cancers sufferers who have been hospitalized for COVID had a 36% greater danger of long-COVID analysis and a 48% greater danger of lengthy COVID–suitable signs than non-infected sufferers, the general incidence was modest, the authors famous, and the dangers didn’t differ considerably from these related to seasonal flu hospitalizations.
“These findings recommend that COVID-19 vaccination and boosting stay essential in mitigating lengthy COVID danger amongst immunocompromised sufferers with most cancers throughout endemicity,” the authors concluded.
